Pharmacy News

GlaxoSmithKline presented the results at the ESMO Congress.

Marketing applications for the treatments are currently being reviewed by the EMA.

Marketing applications for the treatments are currently being reviewed by the EMA.

The report found that there is still significant “room for improvement to promote understanding of all cancers and their risk factors."

The drug improved progression-free survival time to a median of 22.1 months, compared to 16.6 months.

The drug more than doubled median radiographic progression-free survival.

The treatment has been approved to reduce the risk of hospitalisation for heart failure in certain patients with type II diabetes.

The National Audit Office report states that despite the extensive preparations, there still remains a “significant amount to do before 31 October.”

The guidance could lead to as many as 634 fewer emergency caesarean sections and 1,308 fewer neonatal admissions in England, per year.

The study is the first prospective global real-world study of a biologic treatment in patients with severe eosinophilic asthma.

The approval is based on two phase III studies, LixiLan-O and LixiLan-L.

Following the positive results of the trial, the companies have announced that the LEAP-001 Phase III study is now underway.

Results offer new insight to support treatment decisions, Takeda says

Hospitals to get upgraded machines under the plans

The government must follow through with its commitment to deliver a comprehensive strategy this Autumn, to address the gaps in vaccination uptake, the Society says

The move comes under the firm's commitment to fight antimicrobial resistance

Labour intends to create state-owned generic drugs company

JZP-258 achieved primary and key secondary endpoints showing significant differences in weekly number of cataplexy attacks and Epworth Sleepiness Scale scores compared to placebo

Procedure carried out on unborn babies with spina bifida could improve their neurodevelopment

NICE has published final draft guidelines rejecting the drug in this setting